Hydroxychloroquine doesnï¾’t benefit hospitalized COVID-19 patients
On Nov. 24, 2020, the National Institutes of Health reported that In a final analysis of study data,…
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine…
COVID-19 | Life Science News | Medicine | Therapeutics | WHO
Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the WHO announced Interim that results from the Solidarity Therapeutics Trial, coordinated by the…
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine reported results from a clinical trial testing…
Largest global study on hydroxychloroquine safety finds increased cardiovascular risk with azithromycin
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
On Jul. 4, 2020, WHO accepted the recommendation from the Solidarity Trialï¾’s International Steering Committee to discontinue the…
The NIH halted clinical trial of hydroxychloroquine
On Jun. 20, 2020, the NIH announced that a clinical trial to evaluate the safety and effectiveness of…
The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquine
On Jun. 15, 2020, the FDA revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and…
COVID-19 | Disease | FDA | Life Science News | Therapeutics
The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatment
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) warned health care providers about a newly…
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
On Jun. 5, 2020, the Chief Investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) trial on hydroxychloroquine…
NIH began clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
On May 14, 2020, a clinical trial was begun to evaluate whether the malaria drug hydroxychloroquine, given together…
Hydroxychloroquine study with in-hospital patients with COVID-19 in New York State not associated with lower in-hospital mortality
On May 11, 2020, a study was published in JAMA Network that attempts to answer the question whether…
First large study of hydroxychloroquine does not support routine use in COVID-19 patients
On May 7, 2020, a study of nearly 1,400 patients with moderate to severe COVID-19 disease at a…
Clinical trial of drug hydroxychloroquine for treatment of COVID-19 began at Montefiore and Einstein
On Apr. 29, 2020, researchers at Montefiore Health System and Albert Einstein College of Medicine announced that they…
FDA warned of ‘Off-Label’ use of antimalarial drugs hydroxychloroquine and chloroquine to treat COVID-19 patients
On Apr. 24, 2020 the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication regarding known…
Hydroxychloroquine study reported no benefit from malaria drug in Veteran Affairs virus study
On Apr. 21, 2020, a study posted on medRxiv found no evidence that use of hydroxychloroquine, either with…
Expert US panel developed NIH treatment guidelines for COVID-19
On Apr. 21, 2020, A panel of U.S. physicians, statisticians, and other experts developed treatment guidelines for coronavirus…
Biotechnology | COVID-19 | Disease | FDA | Life Science News | Therapeutics
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients
On Apr. 20, 2020, Novartis has reached an agreement with the FDA to proceed with a Phase III…
FDA approved first therapy for children with debilitating and disfiguring rare disease
On Apr. 13, 2020 the FDA announced that given the increased demand for chloroquine phosphate and hydroxychloroquine sulfate,…
Alberta Hope COVID-19 study tested early treatment option
On Apr. 13, 2020, a province wide trial was announced that will investigate the effectiveness of hydroxychloroquine (HCQ)…
Washington University launched Clinical trial to evaluate COVID-19 treatment
On Apr. 9, 2020, Washington University School of Medicine in St. Louis launched a clinical trial for patients…
NIH began clinical trial of hydroxychloroquine as potential therapy for COVID-19
On Apr. 9, 2020, the first participants were enrolled in the trial at Vanderbilt University Medical Center, Nashville,…
Penn Medicine launched trial to evaluate hydroxychloroquine to treat, prevent COVID-19
On Apr. 3, 2020, a trial led by the Perelman School of Medicine at the University of Pennsylvania…
FDA issued EUA to allow hydroxychloroquine sulfate and chloroquine phosphate products from Strategic National Stockpile to be distributed
On Mar. 28, 2020, the FDA issued an Emergency Use Authorization (EUA) to allow hydroxychloroquine sulfate and chloroquine…
Amneal Pharmaceuticals donated hydroxychloroquine sulfate to state of Texas
On Mar. 26, 2020, Amneal Pharma announced it had donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State…
Amneal accelerated distribution and production of hydroxychloroquine sulfate to meet potential needs of COVID-19 patients
On Mar. 20, 2020, Amneal Pharma announced that it was responding to the national COVID-19 health emergency by…
Novartis commited to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
On Mar. 20, 2020, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine…
Teva donated potential COVID-19 treatment, hydroxychloroquine sulfate tablets to hospitals nationwide
On Mar. 19, 2020, Teva announced the immediate donation of more than 6 million doses of hydroxychloroquine sulfate…
COVID-19 | FDA | Medicine | Therapeutics
Mylan ramped up U.S. manufacturing of hydroxychloroquine sulfate tablets to meet potential COVID-19 patient needs
On Mar. 19, 2020, Mylan announced it had restarted production of hydroxychloroquine sulfate tablets at its West Virginia…